Imagine surviving leukaemia only to have your new bone marrow turn on you like a mutinous houseguest. That, in brutal shorthand, is graft-versus-host disease — the cruel twist that haunts thousands of bone marrow transplant patients every year.
Now a new kind of cell therapy, built around the immune system's own "peacekeepers", may finally be ready to change that story.
The treatment is called Orca-T, and it's on the cusp of becoming the first regulatory T cell therapy ever approved by the US Food and Drug Administration. The agency is currently reviewing its application, with a fresh decision deadline of 6 July 2026, after a routine paperwork extension earlier this spring.
What on earth is a regulatory T cell?
Your immune system is essentially a very enthusiastic army. It hunts down invaders — viruses, bacteria, rogue cancer cells — and destroys them. The problem is that, left unchecked, it sometimes turns on the body it's meant to protect.
Enter the regulatory T cell, or "T-reg". Think of it as the calm sergeant who tells the troops to stand down. T-regs stop the immune system attacking healthy tissue. The scientists who discovered them won the 2025 Nobel Prize in Physiology or Medicine, according to Scientific American, which flagged T-reg therapies as one of the most exciting health stories to watch in 2026.
Why this matters for transplant patients
Bone marrow transplants are a lifeline for people with blood cancers like acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes. But when donor cells settle in, they can mistake the patient's own body for the enemy. The result — graft-versus-host disease, or GVHD — can cause rashes, gut damage, organ failure and death.
Orca-T, made by California biotech Orca Bio, tries to head that off at the pass. It takes a donor's blood, then uses single-cell precision sorting to assemble a bespoke cocktail of stem cells, regulatory T cells and conventional T cells. The peacekeepers are baked in from the start.
In the company's pivotal Precision-T phase 3 trial, the therapy hit its primary goal: significantly more patients survived without moderate-to-severe chronic GVHD compared with a standard transplant.
Data presented at the 2026 Tandem Meetings in February were striking. In a focused group of patients aged 18 to 65 with myelodysplastic syndromes receiving a matched-donor transplant, the Orca-T group showed 100 per cent overall survival at one, two and three years. The historical comparison group, treated with the current standard, was at 80 per cent at one year and 62 per cent by year three.
Non-relapse mortality? Zero per cent, against nearly 10 per cent for the older approach.
A short delay, not a setback
The FDA had originally been expected to decide by 6 April 2026. Earlier this month, the agency pushed that to 6 July 2026 after Orca Bio submitted updated manufacturing information. Crucially, regulators classified the change as a "Major Amendment" on paperwork grounds — not a flag over safety or effectiveness — and asked for no new clinical data.
"Our continued focus is on preparing for the potential approval and commercial launch of Orca-T," chief executive Nate Fernhoff said in a statement. The company is still aiming for a mid-2026 rollout if the green light comes.
Bigger horizons
If Orca-T crosses the finish line, the implications stretch well beyond transplant wards. Researchers are testing similar T-reg approaches for autoimmune conditions — the family of diseases, including type 1 diabetes, multiple sclerosis and lupus, where the immune system attacks the body it lives in.
For now, though, the story belongs to the patients facing a transplant this summer. After decades of research, the peacekeeper cells may finally be reporting for duty.
